CA
ACET icon

Crewe Advisors’s Adicet Bio ACET Stock Holding History

Crewe Advisors’s Portfolio ACET Stock Details ACET Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-11
Closed -$2K – 1019
2022
Q3 		$2K Hold
11
– – ﹤0.01% 1012
2022
Q2 		$3K Buy
+11
New +$2.42K ﹤0.01% 862

Other funds holding ACET

O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
CAC
Cowen and Company New York $2.97B AUM 105.26% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
A
Abingworth London, United Kingdom $307M AUM 93.47% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return

Crewe Advisors's ACET Position: Q4 2022 in Review

Crewe Advisors sold out of Adicet Bio (ACET) in Q4 2022, closing a stake of 11 shares — an estimated $2K sold.

Crewe Advisors first reported a position in ACET in Q2 2022 and held it in 2 quarters. The position peaked at $3K in Q2 2022. 100 funds tracked by Wall St. Rank hold ACET as of Q4 2022.

  • Crewe Advisors reported no remaining Adicet Bio position as of Q4 2022 after selling out during the quarter.
  • Crewe Advisors sold 11 Adicet Bio shares in Q4 2022, an estimated $2K.
  • Crewe Advisors first reported a position in Adicet Bio in Q2 2022 and held it in 2 quarters.
  • Crewe Advisors's Adicet Bio position peaked at $3K in Q2 2022.
  • 100 funds tracked by Wall St. Rank held Adicet Bio as of Q4 2022.

Based on Crewe Advisors's 13F filing for Q4 2022, filed 8 Feb 2023.